Trial record 1 of 8 for:    opt-80
Previous Study | Return to List | Next Study

A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by Astellas Pharma Inc
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: June 30, 2014
Last updated: February 3, 2016
Last verified: February 2016
The primary objective of this study is to investigate the safety and efficacy of OPT-80 versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).

Condition Intervention Phase
Clostridium Difficile
Drug: OPT-80
Drug: vancomycin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: OPT-80 Phase III Study -A Multi-center, Double Blinded, Randomized, Parallel Group Study To Compare The Safety, Pharmacokinetics And Efficacy of OPT-80 With Vancomycin In Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Global cure rate [ Time Frame: Up to 38 days ] [ Designated as safety issue: No ]
    Global cure rate is the rate of the subjects satisfying both of the following: being cured at the completion of study drug administration; without recurrence during the follow-up period

Secondary Outcome Measures:
  • Cure rate [ Time Frame: Day 10 -11 of the study period ] [ Designated as safety issue: No ]
  • Recurrence rate of CDAD [ Time Frame: during the 4-week follow-up period, up to Day 38 ] [ Designated as safety issue: No ]
  • Time to resolution of diarrhea [ Time Frame: up to 38 days ] [ Designated as safety issue: No ]
  • Microbiological efficacy [ Time Frame: Up to 38 days ] [ Designated as safety issue: No ]
  • Plasma concentration of OPT-80(fidaxomicin) [ Time Frame: Before administration, Day 1 and Day 10-11 ] [ Designated as safety issue: No ]
  • Plasma concentration of OP-1118 [ Time Frame: Before administration, Day 1 and Day 10-11 ] [ Designated as safety issue: No ]
  • Fecal concentration of OPT-80(fidaxomicin) [ Time Frame: Day 10-11 ] [ Designated as safety issue: No ]
  • Fecal concentration of OP-1118 [ Time Frame: Day 10-11 ] [ Designated as safety issue: No ]
  • Safety assessed by the incidence of adverse events, vital signs, ECGs and laboratory tests [ Time Frame: Up to 38 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 210
Study Start Date: May 2014
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OPT-80 group Drug: OPT-80
Other Name: fidaxomicin
Active Comparator: Vancomycin group Drug: vancomycin

Detailed Description:
This is a multicenter, double-blind, randomized, parallel group study. The subjects who meet all of the inclusion criteria and none of the exclusion criteria will be randomized, and will orally receive either OPT-80 twice daily or vancomycin powder four times daily for 10 days. A follow-up investigation will be performed 28 (±3) days after the completion of study drug administration.

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Inpatients who have symptoms of CDAD as defined by;

    • (1)Diarrhea: with ≥4 unformed bowel movements (or ≥200 mL unformed stool for subjects having rectal collection devices) and
    • (2)Presence of either toxin A and/or B of C. difficile in the stool
  • Subjects who have not received antibacterials (vancomycin, metronidazole, aiming at CDAD treatment before the study

Exclusion Criteria:

  • Life-threatening or fulminant CDAD
  • Ileus paralytic or toxic megacolon
  • Likelihood of death before the completion of study from any cause
  • Concurrent use of oral vancomycin, metronidazole, aiming at the treatment of CDAD
  • The anticipated need to continue other antibacterials for a period exceeding seven days from providing the informed consent
  • Subjects who in the opinion of the investigator require other drugs to control diarrhea
  • Need of change in dosage regimen of opiates during the study period
  • Need of change in dosage regimen of probiotic products during the study period
  • History/complications of ulcerative colitis or Crohn's disease
  • Multiple occurrences of CDAD within the past three months
  • Hypersensitivity to vancomycin
  • Previous exposure to OPT-80 (fidaxomicin)
  • Female patients who are pregnant, breastfeeding or possibly pregnant, or wishing to become pregnant during the course of study
  • Participation in other clinical research studies or Post Marketing Clinical Trials utilizing an investigational agent within one month prior to providing the informed consent or within five half-lives of the investigational agent, whichever is longer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02179658

Contact: Clinical Development Administration Dept

Chubu, Japan
Chugoku, Japan
Hokkaido, Japan
Kanto, Japan
Kinnki, Japan
Kyushu, Japan
Touhoku, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Medical Director Astellas Pharma Inc
  More Information

No publications provided

Responsible Party: Astellas Pharma Inc Identifier: NCT02179658     History of Changes
Other Study ID Numbers: 2819-CL-3002 
Study First Received: June 30, 2014
Last Updated: February 3, 2016
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Astellas Pharma Inc:

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses processed this record on February 11, 2016